The official advocacy organization for pharmacist women in the United States
Over 6 Million posts, comments and reactions in 2020
60,000+ Followers on social media platforms
The Largest Community of Women Pharmacists in the US
Founded in 2017, Pharmacists Moms Group was created to provide women pharmacists the opportunity to network, collaborate and offer genuine feedback in a closed-door, trusted setting. The organization has quickly grown to over 45,000 members and 60,000 followers on our social media platforms.
While we may not be able to control what happens to us, we can ALWAYS control how we respond. Working on self-awareness and self-improvement will certainly create positive habits to help you when you are stuck.
Read on to learn more about Jennifer’s path to pharmacy ownership, and to learn how COVID-19 and the Oregon wildfires have impacted her business.
Miss America 2020, Camille Schrier, has been a proud, self-described “science nerd” for as long as she can remember. We caught up with Camille to get a student’s perspective on the future of the profession.
At 3 and 6 months, rivaroxaban was found to be as effective and safe as apixaban in the composite outcome of recurrent venous thromboembolism or bleeding-related hospitalization.
The phase 3 clinical trial shows that the 5-year OS for patients with HR+/HER2- advanced breast cancer in the abemaciclib plus fulvestrant group was 41.2% vs 29.2% for the placebo arm.
OP-1250 and palbociclib showed “enhanced suppression of tumor growth” in preclinical mouse model studies, according to expert who presented his findings in a poster at the San Antonio Breast Cancer Symposium 2022.
Expert sits with Pharmacy Times to share the promising results of a study that evaluated the safety of a new antibody drug conjugate with radiation therapy.
Results from the phase 3 CAPItello-291 clinical trial show that the combination doubled the median progression-free survival compared with the placebo in patients with HR-positive, HER2-negative advanced breast cancer.
The decision is updated from a 2017 recommendation to screen people for obstructive sleep apnea, which can lead to daytime sleepiness and other adverse outcomes.